Editors' ChoiceCancer

A (synthetic) lethal weapon for cancer

See allHide authors and affiliations

Science Translational Medicine  18 Apr 2018:
Vol. 10, Issue 437, eaat4477
DOI: 10.1126/scitranslmed.aat4477

You are currently viewing the abstract.

View Full Text

Abstract

ROS1 inhibition in E-cadherin–deficient tumors leads to synthetic lethality, which could be exploited for the selective treatment of breast cancer patients.

View Full Text